China Usa Israel virus covid-19 RNA China Usa Israel

Covid-19: Can-Fite, Lattice Biologics study treatment approaches

Reading now: 998
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Israel biotechnology company Can-Fite BioPharma has partnered with the Lewis Katz School of Medicine at Temple University in the US to test the anti-viral activity of Piclidenoson against Covid-19.

Initially, the project, led by Dr Kamel Khalili, will evaluate the drug’s effect on coronaviruses viral load in a mammalian cell model system.

Piclidenoson is undergoing a Phase III clinical trial to treat rheumatoid arthritis. Previously, the drug demonstrated anti-viral activity against HIV and HCC, which are single-stranded RNA viruses.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA